Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report

J Hematol Oncol. 2009 Apr 28:2:19. doi: 10.1186/1756-8722-2-19.

Abstract

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Castleman Disease / complications*
  • Castleman Disease / drug therapy*
  • Castleman Disease / pathology
  • Humans
  • Male
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasms, Multiple Primary / drug therapy*
  • Neoplasms, Multiple Primary / pathology
  • Pyrazines / therapeutic use*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib